French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple sclerosis in early 2024.
Indian shares fell on Wednesday after hitting five-month highs for three sessions in a row, as caution set in ahead of the U.S. Congress's approval of the debt deal and fresh concerns about China's stuttering economic recovery weighed on the sentiment.
Amylyx Pharmaceuticals Inc said on Tuesday that a European regulatory panel had taken a negative view on its amyotrophic lateral sclerosis (ALS) treatment, stalling the company's plans on introducing its first commercial drug in the region.
The European Union and drugmakers Pfizer and BioNTech said on Friday they had reached a deal to amend a COVID-19 vaccine contract, cutting the number the EU must buy and pushing the delivery deadline to 2026.